Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma.
about
Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinomaPhase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosisUnderstanding the interplay between host immunity and Epstein-Barr virus in NPC patientsTherapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinomaNovel approach to the formulation of an Epstein-Barr virus antigen-based nasopharyngeal carcinoma vaccineEmerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in OncologyMetronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma.Mice with human immune system components as in vivo models for infections with human pathogens.Immunophenotyping at the time of diagnosis distinguishes two groups of nasopharyngeal carcinoma patients: implications for adoptive immunotherapy.Epstein-barr virus vaccines.Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma.Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus-Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma.Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disordersEpstein-barr virus nuclear antigen 1: from immunologically invisible to a promising T cell target.Identification of Four-Jointed Box 1 (FJX1)-Specific Peptides for Immunotherapy of Nasopharyngeal Carcinoma.A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma.HLA associations with nasopharyngeal carcinoma.Virus-specific CD4+ T cells: ready for direct attack.Therapeutic vaccine targeting Epstein-Barr virus latent protein, LMP1, suppresses LMP1-expressing tumor growth and metastasis in vivo.Professional antigen presenting cells in human herpesvirus 8 infection.Protection against laryngeal and pharyngeal carcinoma: Heterozygous vs. homozygous deletions of GSTM1 and GSTT1Targeting the nuclear antigen 1 of Epstein-Barr virus to the human endocytic receptor DEC-205 stimulates protective T-cell responses.Immunotherapies for Hodgkin's lymphoma.Immune escape by Epstein-Barr virus associated malignancies.Chimerically fused antigen rich of overlapped epitopes from latent membrane protein 2 (LMP2) of Epstein-Barr virus as a potential vaccine and diagnostic agentGSTM1 and GSTT1 polymorphisms and nasopharyngeal cancer risk: an evidence-based meta-analysisHuman dendritic cells and transplant outcome.NBN Gene Polymorphisms and Cancer Susceptibility: A Systemic Review.GSTM1 polymorphism is related to risks of nasopharyngeal cancer and laryngeal cancer: a meta-analysis.Novel Molecular Targets for Chemoprevention in Malignancies of the Head and Neck.CD4+ T-cell responses to Epstein-Barr virus nuclear antigen EBNA1 in Chinese populations are highly focused on novel C-terminal domain-derived epitopes.RANK expression in EBV positive nasopharyngeal carcinoma metastasis: a ready-to-treat target?Epstein-Barr Virus as a Promising Immunotherapeutic Target for Nasopharyngeal Carcinoma Treatment.Constructing TC-1-GLUC-LMP2 Model Tumor Cells to Evaluate the Anti-Tumor Effects of LMP2-Related Vaccines.Role of Epstein-Barr Virus in the Pathogenesis of Head and Neck Cancers and Its Potential as an Immunotherapeutic TargetInterleukin-18 promoter genotype is associated with the risk of nasopharyngeal carcinoma in Taiwan
P2860
Q24610485-E43997DE-D368-4107-8531-1216AF96C90BQ24657081-8E974FA2-DF43-43EB-880B-D89D25BBDD25Q26823898-8BC0BA08-5411-44E4-9192-C233AECFF7A7Q27016002-382C2081-DC15-4FD0-8D1F-3E30FE666DC2Q28749468-99A3AB26-D517-4106-A74D-1F7C7B65312FQ30438965-ABDCED16-752A-40CE-9F8D-93CF49A8FB76Q30846827-28592723-637B-4195-B81A-0733835616FFQ34920166-CB5836CC-757A-4D36-9E25-31EA35706981Q35005421-47F65259-B534-40CB-8BB3-D2CE79AB9C59Q35053650-BA1BDBFD-1013-4006-A2C5-BBCD6047C0DDQ35507358-65A05E16-65DA-4935-9CBF-E8EFC0C4A751Q35684896-75131318-D50B-4712-A692-969CAE7450A4Q35738744-C20537DF-1284-42E7-96A6-FB1D306C09A9Q35775750-5611EBB3-1539-4642-B2A7-78407F811236Q35832185-660C4029-DF38-4208-A509-A2592E4E9DCCQ35857642-FF7EE86D-8F96-4409-8B09-2F9EFE265304Q36125265-83A73BA5-7B1D-4E64-8C6D-EDA8CD05AF29Q36228485-F97676C4-6D60-4371-A8C9-548F34713672Q36241068-F2228C66-AD16-419B-BB0D-13942A92C61AQ36546999-6582B6A8-AEA3-4ABA-AFAD-63D2D2764ACBQ36737429-7EB87C46-B5CA-493A-95F1-36F4019F7297Q36835091-1EA30774-69DB-463C-8C76-76C323E68F64Q37006427-CD41B57C-07C8-4515-90FF-1199100155B4Q37041507-F0BC5FE7-4BB5-4B0D-A62F-65AAF8CFD41AQ37101134-472F4CA6-3CFF-4D7B-A5A5-70824A68185CQ37158484-69528D0A-365B-417A-8F02-4FE517DEDC02Q37190393-5615582E-303D-4681-8C3B-C741030F10BBQ37402588-F056B42B-450F-4D30-B8F4-A5FA3B4A62DCQ37696716-7252B73C-7190-4914-AA30-DDB1125781CDQ38635035-AC16553F-76D0-4664-A64A-581C74AE9BB5Q42170835-77424FC7-1746-4D1F-B612-4D04EB46A9A8Q47106594-57E17555-C4F0-4FFB-9433-8104F839EBC2Q49787173-7C044EE3-C9B0-41E5-AF25-6C9221ECF045Q54249887-32DBC69B-FCD2-498F-829B-471F0275099CQ57176933-2CDDC2ED-E18D-436A-9C99-092629D49F4AQ59125989-75FCAC1A-3F5E-4DC3-999A-026AD4E0EFE2
P2860
Immunization with Epstein-Barr Virus (EBV) peptide-pulsed dendritic cells induces functional CD8+ T-cell immunity and may lead to tumor regression in patients with EBV-positive nasopharyngeal carcinoma.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Immunization with Epstein-Barr ...... tive nasopharyngeal carcinoma.
@en
Immunization with Epstein-Barr Virus
@nl
type
label
Immunization with Epstein-Barr ...... tive nasopharyngeal carcinoma.
@en
Immunization with Epstein-Barr Virus
@nl
prefLabel
Immunization with Epstein-Barr ...... tive nasopharyngeal carcinoma.
@en
Immunization with Epstein-Barr Virus
@nl
P2093
P1433
P1476
Immunization with Epstein-Barr ...... itive nasopharyngeal carcinoma
@en
P2093
Alan B Rickinson
Chao-Long Chen
Chen-Lung Lin
Paul Kwong Hang Tam
Shiuh-Lin Hwang
Steve P Lee
Tzong-Hsien Lee
Wei-Feng Lo
Yu-Fan Cheng
P304
P407
P577
2002-12-01T00:00:00Z